SSG
CAPR icon

Summit Securities Group’s Capricor Therapeutics CAPR Stock Holding History

Summit Securities Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Buy
+682
New +$20.7K ﹤0.01% 758

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Summit Securities Group's CAPR Position: Q2 2026 in Review

Summit Securities Group opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 682 shares worth $16.4K. The stake represents ﹤0.01% of the portfolio and ranks #758 among its holdings.

170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Summit Securities Group held 682 shares of Capricor Therapeutics worth $16.4K as of Q2 2026.
  • Capricor Therapeutics was a new Summit Securities Group position in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #758 holding.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.